BDX vs JNJ Comparison: AI Score, Valuation, Performance and Upside
Compare Becton Dickinson and Johnson & Johnson by diagnostics revenue, MedTech breadth, drug pipeline vs device growth, dividend history, and valuation.
Use this Becton Dickinson vs Johnson & Johnson comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
JNJ holds the edge across 3 of 5 key metrics in this comparison. JNJ has delivered stronger 1-year price return (+52.22% vs -15.51%), though BDX has the better forward P/E setup (11.79x vs 19.73x for JNJ). JNJ leads on both revenue growth (6.60%) and operating margin (28.61%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BDX (+13.40%) than for JNJ (+6.68%).
| Metric | BDX | JNJ |
|---|---|---|
| AI score | 40.0 | 43.1 |
| AI rank | #1154 | #874 |
| Latest close | $153.16 | $255.63 |
| 1M return | +8.85% | +10.52% |
| 6M return | -25.72% | +17.26% |
| 1Y return | -15.51% | +52.22% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BDX | JNJ |
|---|---|---|
| 1Y ago | $8.39K (-16.1%) started 2025-07-23 | $15.12K (+51.2%) started 2025-07-23 |
| 5Y ago | $7.06K (-29.4%) started 2021-07-26 | $18.54K (+85.4%) started 2021-07-26 |
| 10Y ago | $11.76K (+17.6%) started 2016-07-25 | $34.12K (+241.2%) started 2016-07-25 |
Hypothetical — past performance does not guarantee future results.
| Metric | BDX | JNJ |
|---|---|---|
| Market cap | $43.58B | $609.12B |
| Trailing P/E | 27.60 | 29.32 |
| Forward P/E | 11.79 | 19.73 |
| Price/Sales | N/A | 4.18 |
| EV/Revenue | 2.70 | 6.56 |
| Analyst target | $179.36 | $269.95 |
| Target upside | +13.40% | +6.68% |
| Metric | BDX | JNJ |
|---|---|---|
| Revenue growth | 5.20% | 6.60% |
| Earnings growth | 28.60% | -1.00% |
| EPS growth | +28.60% | -1.00% |
| FCF margin | +20.39% | +12.78% |
| Operating margin | 14.74% | 28.61% |
| Profit margin | 5.12% | 21.48% |
| ROIC proxy | 6.67% | 26.42% |
| Return on equity | 6.67% | 26.42% |
| Dividend yield | 2.66% | 2.12% |
| Beta | 0.27 | 0.23 |
| Debt/equity | 71.60 | 67.73 |
| Current ratio | 0.94 | 1.02 |
| Quick ratio | 0.35 | 0.69 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | BDX | JNJ |
|---|---|---|---|
| 1Y | Growth | -16.11% | +51.17% |
| CAGR | -16.15% | +51.32% | |
| Sharpe ratio | -0.55 | 2.14 | |
| Max drawdown | 33.00% | 10.96% | |
| Max daily drop | 17.22% | 2.69% | |
| Max wkly drop | 16.86% | 6.22% | |
| 5Y | Growth | -33.38% | +65.60% |
| CAGR | -7.82% | +10.63% | |
| Sharpe ratio | -0.38 | 0.41 | |
| Max drawdown | 48.93% | 18.41% | |
| Max daily drop | 18.13% | 7.59% | |
| Max wkly drop | 20.00% | 9.18% | |
| 10Y | Growth | +2.99% | +160.32% |
| CAGR | +0.30% | +10.05% | |
| Sharpe ratio | -0.05 | 0.37 | |
| Max drawdown | 48.93% | 27.37% | |
| Max daily drop | 18.13% | 10.04% | |
| Max wkly drop | 20.00% | 13.25% |
| Category | BDX | JNJ |
|---|---|---|
| Company | BDX | JNJ |
| Sector | Healthcare | Healthcare |
| Industry | N/A | Drug Manufacturers - General |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.